Shanghai Junshi Biosciences Co Денежные средства на акцию
Что обозначает Денежные средства на акцию в Shanghai Junshi Biosciences Co?
Денежные средства на акцию Shanghai Junshi Biosciences Co., Ltd. является 3.80
Какое определение для Денежные средства на акцию?
Денежные средства на акцию - это наличные денежные средства компании, поделенные на акции компании в обращении.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Денежные средства на акцию компаний в Health Care сектор на OTC по сравнению с Shanghai Junshi Biosciences Co
Что делает Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Компании с денежные средства на акцию похож на Shanghai Junshi Biosciences Co
- Alcon имеет Денежные средства на акцию из 3.80
- Velan имеет Денежные средства на акцию из 3.80
- Hello Inc имеет Денежные средства на акцию из 3.80
- Changshouhua Food имеет Денежные средства на акцию из 3.80
- Cboe Global Markets имеет Денежные средства на акцию из 3.80
- China Everbright имеет Денежные средства на акцию из 3.80
- Shanghai Junshi Biosciences Co имеет Денежные средства на акцию из 3.80
- La Francaise des Jeux Societe anonyme имеет Денежные средства на акцию из 3.81
- Stepan Co имеет Денежные средства на акцию из 3.81
- Aurea SA имеет Денежные средства на акцию из 3.81
- CK Infrastructure имеет Денежные средства на акцию из 3.81
- Tencent имеет Денежные средства на акцию из 3.81
- SES SA имеет Денежные средства на акцию из 3.81